Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Perrigo, PFI, Granutec begin private label cimetidine/ranitidine promos to trade.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

PERRIGO, PFI, GRANUTEC START GENERIC CIMETIDINE/RANITIDINE PROMOS, beginning with the first big push to the trade at the Private Label Manufacturer's Association annual trade show in Chicago Nov. 16-19. The three generic drug companies are the first to begin marketing the next big private label OTC, the H2 antagonists, in anticipation of the termination of marketing exclusivity and the companies receiving ANDA approvals for generic versions of the drugs. Tagamet HB 200 (cimetidine) from SmithKline Beecham loses exclusivity June 19, and Glaxo Wellcome's Zantac 75 (ranitidine) loses marketing exclusivity Dec. 19, 1998.

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

US FDA’s Vaccine Office Emerges From Non-COVID-19 Backlog

AstraZeneca’s Farxiga Authorized Generic Aims To Broaden Access As Medicare Price Cut Looms

US FDA Adcomm Reform: Does Listening Session Suggest No Major Near-Term Changes?

It’s Official: FDA Drops Final Rule On LDTs

See All
UsernamePublicRestriction

Register

PS087788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By